{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T09:11:25Z","timestamp":1785834685161,"version":"3.56.0"},"reference-count":59,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2014]]},"DOI":"10.1536\/ihj.14-194","type":"journal-article","created":{"date-parts":[[2014,8,10]],"date-time":"2014-08-10T23:20:58Z","timestamp":1407712858000},"page":"386-390","source":"Crossref","is-referenced-by-count":11,"title":["Therapeutic Potential of \u03b1-Glucosidase Inhibitors to Prevent Postprandial Endothelial Dysfunction"],"prefix":"10.1536","volume":"55","author":[{"given":"Toru","family":"Kato","sequence":"first","affiliation":[{"name":"Department of Clinical Research, Tochigi Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Node","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Renal Medicine, Saga University Faculty of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Dinneen S, Gerich JE, Rizza R. Carbohydrate metabolism in non-insulin-dependent diabetes mellitus. N Engl J Med 1992; 327: 707-13. (Review)","DOI":"10.1056\/NEJM199209033271007"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999; 22: 920-4.","DOI":"10.2337\/diacare.22.6.920"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-405.","DOI":"10.1001\/archinte.161.3.397"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Ceriello A. The post-prandial state and cardiovascular disease: relevance to diabetes mellitus. Diabetes Metab Res Rev 2000; 16: 125-32. (Review)","DOI":"10.1002\/(SICI)1520-7560(200003\/04)16:2<125::AID-DMRR90>3.0.CO;2-4"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Node K, Inoue T. Postprandial hyperglycemia as an etiological factor in vascular failure. Cardiovasc Diabetol 2009; 8: 23. (Review)","DOI":"10.1186\/1475-2840-8-23"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999; 84: 489-97. (Review)","DOI":"10.1161\/01.RES.84.5.489"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Conaway DG, O\u2019Keefe JH, Reid KJ, Spertus J. Frequency of undiagnosed diabetes mellitus in patients with acute coronary syndrome. Am J Cardiol 2005; 96: 363-5.","DOI":"10.1016\/j.amjcard.2005.03.076"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Leiter LA, Ceriello A, Davidson JA, <i>et al<\/i>; International Prandial Glucose Regulation Study Group. Postprandial glucose regulation: new data and new implications. Clin Ther 2005; 27: S42-56. (Review)","DOI":"10.1016\/j.clinthera.2005.11.020"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Bonora E, Corrao G, Bagnardi V, <i>et al<\/i>. Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus. Diabetologia 2006; 49: 846-54.","DOI":"10.1007\/s00125-006-0203-x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Cavalot F, Petrelli A, Traversa M, <i>et al<\/i>. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 2006; 91: 813-9.","DOI":"10.1210\/jc.2005-1005"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Hirata Y, Nagata D, Suzuki E, Nishimatsu H, Suzuki J, Nagai R. Diagnosis and treatment of endothelial dysfunction in cardiovascular disease. Int Heart J 2010; 51: 1-6. (Review)","DOI":"10.1536\/ihj.51.1"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Anderson TJ. Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol 1999; 34: 631-8. (Review)","DOI":"10.1016\/S0735-1097(99)00259-4"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Marfella R, Verrazzo G, Acampora R, <i>et al<\/i>. Glutathione reverses systemic hemodynamic changes by acute hyperglycemia in healthy subjects. Am J Physiol 1995; 268: E1167-73.","DOI":"10.1152\/ajpendo.1995.268.6.E1167"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kawano H, Motoyama T, Hirashima O, <i>et al<\/i>. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 1999; 34: 146-54.","DOI":"10.1016\/S0735-1097(99)00168-0"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Shige H, Ishikawa T, Suzukawa M, <i>et al<\/i>. Endothelium-dependent flow-mediated vasodilation in the postprandial state in type 2 diabetes mellitus. Am J Cardiol 1999; 84: 1272-4.","DOI":"10.1016\/S0002-9149(99)00548-2"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Giugliano D, Marfella R, Coppola L, <i>et al<\/i>. Vascular effects of acute hyperglycemia in humans are reversed by L-arginine. Evidence for reduced availability of nitric oxide during hyperglycemia. Circulation 1997; 95: 1783-90.","DOI":"10.1161\/01.CIR.95.7.1783"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Ceriello A, Esposito K, Piconi L, <i>et al<\/i>. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008; 57: 1349-54.","DOI":"10.2337\/db08-0063"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 1997; 100: 2153-7. (Review)","DOI":"10.1172\/JCI119751"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Ihnat MA, Kaltreider RC, Thorpe JE, <i>et al<\/i>. Attenuated superoxide dismutase induction in retinal cells in response to intermittent high versus continuous high glucose. Am J Biochem Biotech 2007; 3: 16-23.","DOI":"10.3844\/ajbbsp.2007.16.23"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Meugnier E, Faraj M, Rome S, <i>et al<\/i>. Acute hyperglycemia induces a global downregulation of gene expression in adipose tissue and skeletal muscle of healthy subjects. Diabetes 2007; 56: 992-9.","DOI":"10.2337\/db06-1242"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004; 25: 10-6.","DOI":"10.1016\/S0195-668X(03)00468-8"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290: 486-94.","DOI":"10.1001\/jama.290.4.486"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Mari A, Gastaldelli A, Foley JE, Pratley RE, Ferrannini E. Beta-cell function in mild type 2 diabetic patients: effects of 6-month glucose lowering with nateglinide. Diabetes Care 2005; 28: 1132-8.","DOI":"10.2337\/diacare.28.5.1132"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Ai M, Tanaka A, Ogita K, Shimokado K. Favorable effects of early insulin secretion by nateglinide on postprandial hyperlipidemia in patients with type 2 diabetes. Diabetes Care 2006; 29: 1180.","DOI":"10.2337\/dc05-2336"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Shimabukuro M, Higa N, Chinen I, Yamakawa K, Takasu N. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study. J Clin Endocrinol Metab 2006; 91: 837-42.","DOI":"10.1210\/jc.2005-1566"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Shimabukuro M, Higa N, Takasu N, Tagawa T, Ueda S. A single dose of nateglinide improves post-challenge glucose metabolism and endothelial dysfunction in Type 2 diabetic patients. Diabet Med 2004; 21: 983-6.","DOI":"10.1111\/j.1464-5491.2004.01272.x"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Kato T, Inoue T, Node K. Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study. Cardiovasc Diabetol 2010; 9:12.","DOI":"10.1186\/1475-2840-9-12"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Tomiyama H, Kohro T, Higashi Y, <i>et al<\/i>. A multicenter study design to assess the clinical usefulness of semi-automatic measurement of flow-mediated vasodilatation of the brachial artery. Int Heart J 2012; 53: 170-5.","DOI":"10.1536\/ihj.53.170"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Inoue T, Matsuoka H, Higashi Y, <i>et al<\/i>. Flow-mediated vasodilation as a diagnostic modality for vascular failure. Hypertens Res 2008; 31: 2105-13. (Review)","DOI":"10.1291\/hypres.31.2105"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Corretti MC, Anderson TJ, Benjamin EJ, <i>et al<\/i>. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-65.","DOI":"10.1016\/S0735-1097(01)01746-6"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. NAVIGATOR Study Group, Holman RR, Haffner SM, McMurray JJ, <i>et al<\/i>. Effects of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362: 1463-76.","DOI":"10.1056\/NEJMoa1001122"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Sawada T, Shiotani H, Terashita D, <i>et al<\/i>. Comparison of effects of \u03b1-Glucosidase inhibitors and glinide drugs on endothelial dysfunction in diabetic patients with coronary artery disease. Circ J 2014; 78: 248-55.","DOI":"10.1253\/circj.CJ-13-0918"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Maruyama C, Imamura K, Teramoto T. Assessment of LDL particle size by triglyceride\/HDL-cholesterol ratio in non-diabetic, healthy subjects without prominent hyperlipidemia. J Atheroscler Thromb 2003; 10: 186-91.","DOI":"10.5551\/jat.10.186"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Karabulut A, Iltumur K, Toprak N, <i>et al<\/i>. Insulin response to oral glucose loading and coronary artery disease in nondiabetics. Int Heart J 2005; 46: 761-70.","DOI":"10.1536\/ihj.46.761"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Arcaro G, Cretti A, Balzano S, <i>et al<\/i>. Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation 2002; 105: 576-82.","DOI":"10.1161\/hc0502.103333"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Cardillo C, Nambi SS, Kilcoyne CM, <i>et al<\/i>. Insulin stimulates both endothelin and nitric oxide activity in the human forearm. Circulation 1999; 100: 820-5.","DOI":"10.1161\/01.CIR.100.8.820"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Duerrschmidt N, Wippich N, Goettsch W, Broemme HJ, Morawietz H. Endothelin-1 induces NAD(P)H oxidase in human endothelial cells. Biochem Biophys Res Commun 2000; 269: 713-7.","DOI":"10.1006\/bbrc.2000.2354"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Kashiwagi A, Shinozaki K, Nishio Y, <i>et al<\/i>. Endothelium-specific activation of NAD(P)H oxidase in aortas of exogenously hyperinsulinemic rats. Am J Physiol 1999; 277: E976-83.","DOI":"10.1152\/ajpendo.1999.277.6.E976"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Zhu Q, Tong Y, Wu T, Li J, Tong N. Comparison of the hypoglycemic effect of acarbose monotherapy in patients with type 2 diabetes mellitus consuming an Eastern or Western diet: a systematic meta-analysis. Clin Ther 2013; 35: 880-99.","DOI":"10.1016\/j.clinthera.2013.03.020"},{"key":"40","unstructured":"40. Ryd\u00e9n L, Grant PJ, Anker SD, <i>et al<\/i>. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2014 (in press)"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Li C, Hung YJ, Qamruddin K, Aziz MF, Stein H, Schmidt B. International noninterventional study of acarbose treatment in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2011; 92: 57-64.","DOI":"10.1016\/j.diabres.2010.12.033"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Schnell O, Mertes G, Standl E. Acarbose and metabolic control in patients with type 2 diabetes with newly initiated insulin therapy. Diabetes Obes Metab 2007; 9: 853-8.","DOI":"10.1111\/j.1463-1326.2006.00666.x"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Pan C, Yang W, Barona JP, <i>et al<\/i>. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med 2008; 25: 435-41.","DOI":"10.1111\/j.1464-5491.2008.02391.x"},{"key":"44","unstructured":"44. Schnell O, Sheu WH, Watada H, Kalra S, Yamamoto N. An alpha-glucosidase inhibitor, acarbose, reduces body weight irrespective of glycemic control status. Diabetes 2013; 62: A553."},{"key":"45","unstructured":"45. Nakhaee A, Sanjari M. Evaluation of effect of acarbose consumption on weight losing in non-diabetic overweight or obese patients in Kerman. J Res Med Sci 2013; 18: 391-4."},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Standl E, Theodorakis MJ, Erbach M, Schnell O, Tuomilehto J. On the potential of acarbose to reduce cardiovascular disease. Cardiovasc Diabetol 2014; 13: 81.","DOI":"10.1186\/1475-2840-13-81"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Aoki K, Kamiyama H, Yoshimura K, Shibuya M, Masuda K, Terauchi Y. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin. Acta Diabetol 2012; 49: 225-30.","DOI":"10.1007\/s00592-011-0322-9"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Narita T, Yokoyama H, Yamashita R, <i>et al<\/i>. Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients. Diabetes Obes Metab 2012; 14: 283-7.","DOI":"10.1111\/j.1463-1326.2011.01526.x"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Qualmann C, Nauck MA, Holst JJ, Orskov C, Creutzfeldt W. Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose). Scand J Gastroenterol 1995; 30: 892-6.","DOI":"10.3109\/00365529509101597"},{"key":"50","unstructured":"50. Yabe D, Watanabe K, Sugawara K, <i>et al<\/i>. Effects of sitagliptin, acarbose and sulfonylureas on postprandial levels of GLP-1 and GIP in Japanese patients with type 2 diabetes. Diabetologia 2011; 54: S342."},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Zheng MY, Yang JH, Shan CY, <i>et al<\/i>. Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly diagnosed type 2 diabetic patients: a preliminary report. Cardiovasc Diabetol 2013; 12: 73.","DOI":"10.1186\/1475-2840-12-73"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 2011; 54: 10-8. (Review)","DOI":"10.1007\/s00125-010-1896-4"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Holst JJ, Knop FK, Vilsb\u00f8ll T, Krarup T, Madsbad S. Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care 2011; 34: S251-7. (Review)","DOI":"10.2337\/dc11-s227"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Kusunoki Y, Katsuno T, Myojin M, <i>et al<\/i>. Effect of additional administration of acarbose on blood glucose fluctuations and postprandial hyperglycemia in patients with type 2 diabetes mellitus under treatment with alogliptin. Endocr J 2013; 60: 431-9.","DOI":"10.1507\/endocrj.EJ12-0290"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Theodorakis MJ, Carlson O, Michopoulos S, <i>et al<\/i>. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab 2006; 290: E550-9.","DOI":"10.1152\/ajpendo.00326.2004"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Hiki M, Shimada K, Kiyanagi T, <i>et al<\/i>. Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH) -. Circ J 2010; 74: 1471-8.","DOI":"10.1253\/circj.CJ-10-0013"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Scott LJ, Spencer CM. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. Drugs 2000; 59: 521-49. (Review)","DOI":"10.2165\/00003495-200059030-00012"},{"key":"58","unstructured":"58. Ahr HJ, Boberg M, Brendel E, Krause HP, Steinke W. Pharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man. Arzneimittelforschung 1997; 47: 734-45."},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Nystr\u00f6m T, Gutniak MK, Zhang Q, <i>et al<\/i>. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004; 287: E1209-15.","DOI":"10.1152\/ajpendo.00237.2004"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/55\/5\/55_14-194\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T03:14:01Z","timestamp":1649906041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/55\/5\/55_14-194\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.14-194","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}